|
Dr. Brenner is a Distinguished Research Professor at the Salk Institute, La Jolla, California and a world-renowned scientist who played an important role in the birth of modern molecular genetics. Among his contributions to the field are the demonstration of the triplet nature of the genetic code with Francis H.C. Crick (co-discoverer of DNA) and work on suppression of chain termination in protein synthesis. His most significant contributions were recently recognized in the award of the 2002 Nobel Prize in Physiology or Medicine to Dr. Brenner and two colleagues for their discoveries concerning the genetic regulation of organ development and programmed cell death. Dr. Brenner has been associated with a number of successful biotechnology companies, including CombiChem, Inc. (acquired by Dupont, NYSE: DD) and Lynx Therapeutics, Inc. (NASDAQ: LYNX). Dr. Brenner received an MB, BCh Degree from the University of Witwatersrand, Johannesburg, and a D.Phil. from the University of Oxford. In 1957, he joined what was to become the Medical Research Council Laboratory of Molecular Biology in Cambridge, England (MRC the British equivalent of the National Institutes of Health). Dr. Brenner served as Director of the MRC Laboratory of Molecular Biology from 1979 to 1986, when he left to take up the Directorship of the MRC Molecular Genetics Unit. For the last ten years Dr. Brenner has worked on the analysis of complex genomes. He was an Honorary Professor of Genetic Medicine at the University of Cambridge and a member of The Scripps Research Institute. He is also the founder of the Molecular Sciences Institute in Berkeley, CA. Dr. Brenner has received numerous awards and appointments to national scientific academies, including the Royal Society and the National Academy of Sciences as a Foreign Associate. Dr. Brenner has known Dr. Goelet since 1978, when Dr. Goelet joined his laboratory as a PhD student. Drs. Brenner and Goelet have had a strong working relationship over the past twenty five years and, in 1998, the team formed Acidophil, LLC and, subsequently, Dihedron Corp. | 